$0.5423
-0.0365-6.31%
Last update: Nov 10, 4:49 AM
Pasithea Therapeutics Corp
KTTANASDAQ
Pasithea Therapeutics fell 25.8% from $0.73 to $0.54, behind the S&P 500's +10.5%. Its worst day was Nov 21 (−31.1%), and its low came Nov 21 at $0.29.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.41 was reported on $0.00 revenue.
+3.1% · S&P 500 0.0%
Pasithea Therapeutics closed at its highest level of the year, 101.1% above where the year started.
Story events cover the past 12 months · Times ET
+38.7%, on 166M shares, the year's heaviest volume · S&P 500 +0.5%
EPS of $-0.89 missed the $-0.45 estimate on $0.00 revenue.
+3.7% · S&P 500 +2.9%
EPS of $-0.12 beat the $-0.45 estimate on $0.00 revenue.
−1.3% · S&P 500 −0.1%
EPS of $-0.16 beat the $-0.16 estimate on $0.00 revenue.
−0.5% · S&P 500 −0.5%
— FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies.
+44.0% · S&P 500 +0.3%
Where it ended: a close of $0.54 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.21).
Nothing in the past 12 months.
All KTTA dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KTTA and SPY from Benzinga historical bars. Not investment advice.
